Marleen FS, Syahruddin E, Hudoyo A, Endarjo S, Hidayat H, Suzanna E. J Respir Indones. 2009;29(4).
Background: Apoptosis plays a key role in the development of malignant tumors. The Bcl-2 oncoprotein is known to promote cell survival that inhibits programmed cell death (apoptosis). The Bcl-2 family of proteins either pro-apoptotic or anti-apoptotic functions might play different roles in carcinogenesis. The fact that Bcl-2 protein was expressed in about 20-60% in non small cell lung cancer (NSCLC) but no data are available on the frequency or clinical importance of its expression in Indonesian lung cancer. We studied Bcl-2 protein expression in post surgery tissues of NSCLC patients and looked for correlation the expression of Bcl-2 protein level with prognosis.
Methods: We have performed a retrospective study in Department of Respiratory Medicine, Persahabatan Hospital, Jakarta Indonesia. Samples were collected from NSCLC patients who have operated during 1997 to 2008. The Bcl-2 protein expression was detected by Immunohistochemistry analysis methods. We used a monoclonal antibody specific for Bcl-2 and have used paraffin block samples from 43 patients undergoing surgery who matched inclusion criteria’s. The possibility that Bcl- 2 expression correlated with survival was investigated with the log-rank test and Kaplan Meier.
Results: Patients characteristics were male 69.8%, female 30.2% with mean age 56.19±8.3 years old. The Bcl-2 protein expression were not detected in 39/43 (90.6%) of samples and it’s were detected in only 4/43 (9.3%) of samples. The expression were found 2/25 (8%) in adenocarcinoma group and 2/18 (11.1%) in squamous-cell carcinomas group. The data have shown that significant difference between Bcl-2 protein expression with pathological stage in T1-T2 (p= 0.024). One-year survival rate was no correlation between patients with Bcl2 positive and negative group and the log-rank test Kaplan Meier Bcl-2 was no significant difference (p= 0.476).
Conclusion: The expression of Bcl-2 protein was detected in 9.3%(4/43) patients with resectable NSCLC using immunohistochemical staining, significant difference with early pT status (T1-2) and it did not predict prognosis.
Keyword : Bcl-2, non small cell lung cancers, pathological stage, 1 year survival, nsclc, oncoprotein, cancer, lung cancer, immunohistochemistry, imunohistokimia, kanker paru, kanker paru karsinoma bukan sel kecil, kpkbsk, non small cell lung carcinoma